Your dedicated portal for the latest clinical news, research developments, emerging trends, CME resources, drug updates, and AI-powered knowledge tools. Updated regularly โ stay ahead.
New multisite Phase III data confirms durable remissions in heavily pre-treated patients receiving next-gen CD19-directed CAR-T constructs with reduced CRS rates.
Read full study (NEJM) โLandmark SURPASS-CVOT trial data published showing semaglutide 2.4mg superiority in MACE reduction vs placebo at 3-year follow-up in high-risk patients.
Read full study (Lancet) โStudy from AIIMS Delhi validates deep learning model for grading DR severity across 42,000 fundus photographs from diverse Indian patient population.
Read in BMJ โUpdated global TB guidelines now endorse the 4-month bedaquiline-pretomanid-linezolid regimen for drug-susceptible TB, reducing treatment burden significantly.
Read WHO guidance โESC 0h/1h algorithm now validated in South Asian populations โ multicenter data from 8 Indian hospitals demonstrates safe rule-out at 1 hour with hsTnI.
Read (ESC) โ12-month follow-up of BEACON-111 trial shows functional cure in 9/10 patients using adenine base editing of BCL11A enhancer.
18-month data from CLARITY-AD confirms significant slowing of disease progression with anti-amyloid monoclonal antibody therapy.
ctDNA surveillance using 84-gene panel from VedaRx-partner lab demonstrates superior early relapse detection vs standard imaging.
Baricitinib 4mg twice daily achieves 68% improvement in muscle enzyme normalization and skin manifestations at 24 weeks.
SECURE trial subgroup analysis confirms superior adherence and outcomes with fixed-dose combination polypill in South Asian populations.
First-in-class THR-ฮฒ agonist pivotal trial MAESTRO-NASH data โ approved indication in India expected Q3 2026 via CDSCO.
Once-yearly subcutaneous injection approved for HIV-1 in adults with multidrug resistance. MRP: โน2,20,000 per injection.
Dual GIP/GLP-1 receptor agonist now approved in India for type 2 diabetes and obesity management. Weekly injection.
First oral factor B inhibitor approved for PNH. Oral once-daily alternative to IV complement inhibitors.
CDSCO reiterates contraindication in CKD Stage 4-5. Review all patients on metformin with declining renal function.
CDSCO issues recall notice for 3 manufacturers' ranitidine lots with NDMA above acceptable limits. Check lot numbers.
Updated prescribing information includes warning for increased risk of aortic aneurysm. Avoid in high-risk vascular patients.
Updated rhythm and rate management strategies, anticoagulation selection including direct oral anticoagulants, and catheter ablation indications.
Read Guideline โUpdated algorithm incorporating SGLT2i and GLP-1 RA early combination therapy, CGM guidance for primary care, and newer targets for South Asian populations.
Read Guideline โUpdated first-line treatment pathways incorporating pembrolizumab + chemo, osimertinib for EGFR-mutant, and amivantamab for Exon 20 insertions.
Read Guideline โBPaL regimen now first-line for XDR-TB; revised shorter regimen for pulmonary drug-susceptible TB endorsed by RNTCP.
Read Protocol โTest and refresh your clinical knowledge with our AI-curated 10-question medical quiz. Updated monthly with latest evidence-based content.
Get curated clinical news, research summaries, drug updates, regulatory alerts, and CME resources delivered to your inbox every month. Trusted by 2,000+ Indian healthcare professionals.